stockportfolio.pro
Stocks / MDGL vs PODD
MDGL vs PODD
Madrigal Pharmaceuticals, Inc. and Insulet Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Madrigal Pharmaceuticals, Inc. (MDGL) | Insulet Corporation (PODD) | |
|---|---|---|
| Market cap | $11.0B | $11.1B |
| Revenue (latest FY) | $958.40M | $2.71B |
| Net income (latest FY) | $-288.28M | $247.10M |
| Revenue growth (5y CAGR) | — | 24.5% |
| Net margin | -30.1% | 9.1% |
| Return on equity | -47.8% | 16.3% |
| P/E ratio | — | 37.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 8 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open MDGL — free Open PODD — freeFrequently asked questions
Which is bigger, MDGL or PODD?
Insulet Corporation is larger by market capitalization — $11.1B versus $11.0B.
Which grows faster, MDGL or PODD?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.